Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation.

Variation in the tryptophan hydroxylase-2 gene (TPH2) coding for the rate-limiting enzyme of serotonin (5-HT) synthesis in the brain modulates responses of limbic circuits to emotional stimuli and has been linked to a spectrum of clinical populations characterized by emotional dysregulation. Here, we tested a set of common single nucleotide polymorphisms (SNPs) in and downstream of the transcriptional control region of TPH2 for association with personality traits and with risk for personality disorders in two cohorts comprising of 336 healthy individuals and 420 patients with personality disorders. Personality dimensions were assessed by the Tridimensional Personality Questionnaire (TPQ) and the revised NEO Personality Inventory (NEO-PI-R). Personality disorders were diagnosed with the Structured Clinical Interview of DSM-IV and were allocated to clusters A, B, and C. Individual SNP and haplotype analyses revealed significant differences in genotype frequencies between controls and cluster B as well as cluster C patients, respectively. In both patient groups, we observed overrepresentation of T allele carriers of a functional polymorphism in the upstream regulatory region of TPH2 (SNP G-703T, rs4570625) which was previously shown to bias responsiveness of the amygdala, a structure critically involved in emotionality. Furthermore, significant effects of TPH2 variants on anxiety-related traits defined primarily by the TPQ Harm Avoidance were found in healthy individuals. The results link potentially functional TPH2 variants to personality traits related to emotional instability as well as to cluster B and cluster C personality disorders. These findings implicate alterations of 5-HT synthesis in emotion regulation and confirm TPH2 as a susceptibility and/or modifier gene of affective spectrum disorders.

[1]  M. Burmeister,et al.  Meta‐analysis of the association between a serotonin transporter promoter polymorphism (5‐HTTLPR) and anxiety‐related personality traits , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[2]  D Saur,et al.  A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function , 2006, Molecular Psychiatry.

[3]  M. Owen,et al.  The genetic basis of complex human behaviors. , 1994, Science.

[4]  P. Weyers,et al.  RELIABILITY AND CONSTRUCT VALIDITY OF THE GERMAN VERSION OF CLONINGER'S TRIDIMENSIONAL PERSONALITY QUESTIONNAIRE , 1995 .

[5]  Ramin V. Parsey,et al.  Effects of tryptophan depletion on the binding of [11C]-DASB to the serotonin transporter in baboons: Response to acute serotonin deficiency , 2005, Biological Psychiatry.

[6]  J. Kennedy,et al.  Gene expression of tryptophan hydroxylase 2 in post-mortem brain of suicide subjects. , 2005, The international journal of neuropsychopharmacology.

[7]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[8]  J. Kennedy,et al.  Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia , 2005, Psychopharmacology.

[9]  Giuseppe Blasi,et al.  Neural mechanisms of genetic risk for impulsivity and violence in humans. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K Konrad,et al.  Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder , 2005, Molecular Psychiatry.

[11]  K. Lesch,et al.  Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on emotional processing. , 2006, Cerebral cortex.

[12]  A. Hariri,et al.  A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity , 2005, Molecular Psychiatry.

[13]  T. Robbins,et al.  The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers , 2002, Psychopharmacology.

[14]  Martin Reuter,et al.  Association between a polymorphism in the promoter region of the TPH2 gene and the personality trait of harm avoidance. , 2007, The international journal of neuropsychopharmacology.

[15]  T. Robbins,et al.  Individual differences in threat sensitivity predict serotonergic modulation of amygdala response to fearful faces , 2005, Psychopharmacology.

[16]  Michael F Egan,et al.  A susceptibility gene for affective disorders and the response of the human amygdala. , 2005, Archives of general psychiatry.

[17]  M. Preisig,et al.  Monoamine Oxidase A and Tryptophan Hydroxylase Gene Polymorphisms , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[18]  Paul Chen,et al.  Serotonin 5-HT1A Receptors Regulate NMDA Receptor Channels through a Microtubule-Dependent Mechanism , 2005, The Journal of Neuroscience.

[19]  K. Lesch,et al.  Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. , 2004, The international journal of neuropsychopharmacology.

[20]  H. Möller,et al.  SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression , 2004, Molecular Psychiatry.

[21]  P. Celada,et al.  Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. , 2004, Cerebral cortex.

[22]  Michael Bader,et al.  Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform , 2003, Science.

[23]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[24]  R. Busch,et al.  A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety , 2004, Molecular Psychiatry.

[25]  R. T. Constable,et al.  Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation , 2005, Journal of Neural Transmission.

[26]  J C Loehlin,et al.  Partitioning environmental and genetic contributions to behavioral development. , 1989, The American psychologist.

[27]  P. Celada,et al.  In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. , 2003, Cerebral cortex.

[28]  Á. Pascual-Leone,et al.  How do we modulate our emotions? Parametric fMRI reveals cortical midline structures as regions specifically involved in the processing of emotional valences. , 2005, Brain research. Cognitive brain research.

[29]  Andreas Reif,et al.  Anxiety-related traits in mice with modified genes of the serotonergic pathway. , 2003, European journal of pharmacology.

[30]  Jing Hua Zhao,et al.  2LD, GENECOUNTING and HAP: computer programs for linkage disequilibrium analysis , 2004, Bioinform..

[31]  V. Arango,et al.  Neuronal Tryptophan Hydroxylase mRNA Expression in the Human Dorsal and Median Raphe Nuclei: Major Depression and Suicide , 2006, Neuropsychopharmacology.

[32]  D. Goldman,et al.  Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. , 2005, Archives of general psychiatry.

[33]  Christian Büchel,et al.  Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter , 2005, Nature Neuroscience.

[34]  P. Costa,et al.  Revised NEO Personality Inventory (NEO-PI-R) and NEO-Five-Factor Inventory (NEO-FFI) , 1992 .

[35]  S. Maier,et al.  Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus , 2005, Nature Neuroscience.

[36]  E. Lander,et al.  Genetic dissection of complex traits science , 1994 .

[37]  M. Nöthen,et al.  Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. , 1999, Human molecular genetics.

[38]  R. Blakely.  Overview: A Rare Opportunity or Just One Less Reason to Be Depressed , 2005, Neuron.

[39]  T. Sotnikova,et al.  Tryptophan Hydroxylase-2 Controls Brain Serotonin Synthesis , 2004, Science.

[40]  T. Robbins,et al.  Cognitive Inflexibility After Prefrontal Serotonin Depletion , 2004, Science.

[41]  E. Shink,et al.  Support for the involvement of TPH2 gene in affective disorders , 2004, Molecular Psychiatry.

[42]  S. Debener,et al.  Dopamine D4 receptor exon III genotype influence on the auditory evoked novelty P3 , 2004, Neuroreport.

[43]  B. Roth,et al.  Control of Serotonergic Function in Medial Prefrontal Cortex by Serotonin-2A Receptors through a Glutamate-Dependent Mechanism , 2001, The Journal of Neuroscience.

[44]  C. Robert Cloninger.  A systematic method for clinical description and classification of personality variants. A proposal. , 1987, Archives of general psychiatry.

[45]  K. Lesch,et al.  CRSN Symposium : Focus on Depression , Part I Symposium du CRSN : le point sur la dépression , première partie Gene – environment interaction and the genetics of depression , 2004 .

[46]  Dragan M. Svrakic,et al.  The Tridimensional Personality Questionnaire: U.S. Normative Data , 1991, Psychological reports.

[47]  T. Robbins,et al.  Serotonergic Modulation of Prefrontal Cortex during Negative Feedback in Probabilistic Reversal Learning , 2005, Neuropsychopharmacology.

[48]  W. Riedel,et al.  Tryptophan, mood, and cognitive function , 2002, Brain, Behavior, and Immunity.

[49]  Susanne Walitza,et al.  Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. , 2006, The international journal of neuropsychopharmacology.

[50]  Cloninger Cr.  A systematic method for clinical description and classification of personality variants: A proposal. , 1987 .

[51]  K. Lesch,et al.  Cluster B Personality Disorders are Associated with Allelic Variation of Monoamine Oxidase A Activity , 2005, Neuropsychopharmacology.